MapLight Therapeutics, Inc. Common Stock (MPLT) Stock Forecast & Price Target
MapLight Therapeutics, Inc. Common Stock · NASDAQ
$12.31+2.40 (+24.28%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering MapLight Therapeutics, Inc. Common Stock, 12 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $30.00 to $52.00, a moderate spread. The average target of $40.82 sits 232% above the current $12.31. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.25 next quarter toward $-3.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy18%
Buy1192%
Hold00%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to MapLight Therapeutics, Inc. Common Stock.
As of Jul, 12 of 12 firms rate MPLT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MPLT EPS & revenue forecast
EPS · NEXT QUARTER
$-1.25
Range $-1.35 – $-1.06 · 7 analysts
Next period, 7 analysts expect MapLight Therapeutics, Inc. Common Stock to earn $-1.25 a share (range $-1.35 – $-1.06), versus — a year earlier. Full-year consensus is $-5.09, growing to $-3.81 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $18.2M next year.
Top analysts covering MapLight Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MPLT.
#1
Ami Fadia
Needham · Rank #90
Buy
$45.00+265.6% to target
Overall win rate
46%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$45.00+265.6% to target
Overall win rate
37%
+ Follow
#3
Sumant Kulkarni
Canaccord Genuity · Rank #278
Buy
$43.00+249.3% to target
Overall win rate
39%
+ Follow
#4
AV
Adam Vogel
Craig-Hallum
Buy
$40.00+224.9% to target
Coverage
—
+ Follow
#5
Sean Laaman
Morgan Stanley
Buy
$34.00+176.2% to target
Coverage
—
+ Follow
MPLT stock forecast FAQ
What is MPLT's average 12-month price target?+
The 11 analysts with a live target average $40.82 for MapLight Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $52.00 high to a $30.00 low.
Is MPLT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 12 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MPLT?+
The Street-high target is $52.00 (UBS), and the Street-low is $30.00 (Leerink Partners). The average of all 11 active targets is $40.82.
How many Wall Street analysts cover MPLT?+
12 analysts have an active rating on MapLight Therapeutics, Inc. Common Stock, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering MPLT?+
Among analysts who currently cover MPLT, Ami Fadia of Needham has the strongest overall Quantellect track record (Rank #90). Their current call is Buy with a $45.00 target.
What is MapLight Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.25 per share (range $-1.35 – $-1.06) across 7 analysts. Full-year EPS is projected at $-5.09, rising to $-3.81 the following year.
How much revenue is MapLight Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $18.2M next year.
Have analysts been upgrading or downgrading MPLT lately?+
As of Jul, 12 of 12 firms rate MPLT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MPLT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
